Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.
Saved in:
| Title: | Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. |
|---|---|
| Authors: | Kim DH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Kwon S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Cha S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Öz RS; Department of Internal Medicine, Hacettepe University Hospital, Ankara, Turkiye., Hong J; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Shin DY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Byun JM; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, KoreaBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. |
| Source: | Therapeutic advances in hematology [Ther Adv Hematol] 2025 Dec 22; Vol. 16, pp. 20406207251406461. Date of Electronic Publication: 2025 Dec 22 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101549589 Publication Model: eCollection Cited Medium: Print ISSN: 2040-6207 (Print) Linking ISSN: 20406207 NLM ISO Abbreviation: Ther Adv Hematol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2040-6207 |
|---|---|
| DOI: | 10.1177/20406207251406461 |
